Abstract
The ribonucleoside analog ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) shows antiviral activity against a variety of RNA viruses and is used in combination with interferon-α to treat hepatitis C virus infection. Here we show in vitro use of ribavirin triphosphate by a model viral RNA polymerase, poliovirus 3Dpol. Ribavirin incorporation is mutagenic, as it templates incorporation of cytidine and uridine with equal efficiency. Ribavirin reduces infectious poliovirus production to as little as 0.00001% in cell culture. The antiviral activity of ribavirin correlates directly with its mutagenic activity. These data indicate that ribavirin forces the virus into `error catastrophe'. Thus, mutagenic ribonucleosides may represent an important class of anti-RNA virus agents.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sidwell, R.W. et al. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl- 1,2,4-triazole-3-carboxamide. Science 177, 705–706 (1972).
Smith, R.A. & Kirkpatrick, W. in Ribavirin, a Broad Spectrum Antiviral Agent Vol. xiii, 237 (Academic, New York, 1980).
De Clercq, E. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Adv. Virus Res. 42, 1–55 (1993).
McHutchison, J.G. et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1485–1492 (1998).
Davis, G.L. et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1493–1499 (1998).
McCormick, J.B. et al. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314, 20–26 (1986).
Wyde, P.R. Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res. 39, 63–79 (1998).
Streeter, D.G. et al. Mechanism of action of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. USA 70, 1174–1178 (1973).
Smith, R.A., Knight, V. & Smith, J.A.D. in Clinical Applications of Ribavirin Vol. xix, 222 (Academic, New York, 1984).
Gilbert, B.E. & Knight, V. Biochemistry and clinical applications of ribavirin. Antimicrob. Agents Chemother. 30, 201–205 (1986).
AFHS Drug Information (American Society of Hospital Pharmacists: SilverPlatter International, Bethesda, Maryland, 2000).
Goswami, B.B., Borek, E., Sharma, O.K., Fujitaki, J. & Smith, R.A. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 89, 830–836 (1979).
Eriksson, B. et al. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 11, 946–951 (1977).
Cassidy, L.F. & Patterson, J.L. Mechanism of La Crosse virus inhibition by ribavirin. Antimicrob. Agents Chemother. 33, 2009–2011 (1989).
Miller, J.P. et al. The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann. NY Acad. Sci. 284, 211–229 (1977).
Arnold, J.J. & Cameron, C.E. Poliovirus RNA-dependent RNA polymerase (3D(pol)). Assembly of stable, elongation-competent complexes by using a symmetrical primer-template substrate (sym/sub). J. Biol. Chem. 275, 5329–5336 (2000).
Gohara, D.W. et al. Poliovirus RNA-dependent RNA Polymerase (3Dpol): Structural, biochemical, and biological analysis of conserved structural motifs A and B. J. Biol. Chem. 275, 25523–25532 (2000).
Herold, J. & Andino, R. Poliovirus requires a precise 5′ end for efficient positive-strand RNA synthesis. J. Virol. 74, 6394–6400 (2000).
Andino, R., Rieckhof, G.E., Achacoso, P.L. & Baltimore, D. Poliovirus RNA synthesis utilizes an RNP complex formed around the 5′-end of viral RNA. EMBO J. 12, 3587–3598 (1993).
Maynell, L.A., Kirkegaard, K. & Klymkowsky, M.W. Inhibition of poliovirus RNA synthesis by brefeldin A. J. Virol. 66, 1985–1994 (1992).
Pfister, T. & Wimmer, E. Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication. J. Biol. Chem. 274, 6992–7001 (1999).
Pincus, S.E., Diamond, D.C., Emini, E.A. & Wimmer, E. Guanidine-selected mutants of poliovirus: mapping of point mutations to polypeptide 2C. J. Virol. 57, 638–646 (1986).
Baltera, R.F., Jr. & Tershak, D.R. Guanidine-resistant mutants of poliovirus have distinct mutations in peptide 2C. J. Virol. 63, 4441–4444 (1989).
Pringle, C.R. Genetic characteristics of conditional lethal mutants of vesicular stomatitis virus induced by 5-fluorouracil, 5-azacytidine, and ethyl methane sulfonate. J. Virol. 5, 559–567 (1970).
Pathak, V.K. & Temin, H.M. 5-Azacytidine and RNA secondary structure increase the retrovirus mutation rate. J. Virol. 66, 3093–3100 (1992).
Holland, J.J., Domingo, E., de la Torre, J.C. & Steinhauer, D.A. Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J. Virol. 64, 3960–3962 (1990).
Lee, C.H. et al. Negative effects of chemical mutagenesis on the adaptive behavior of vesicular stomatitis virus. J. Virol. 71, 3636–3640 (1997).
Irurzun, A., Perez, L. & Carrasco, L. Involvement of membrane traffic in the replication of poliovirus genomes: effects of brefeldin A. Virology 191, 166–175 (1992).
Domingo, E. & Holland, J.J. RNA virus mutations and fitness for survival. Annu. Rev. Microbiol. 51, 151–178 (1997).
Domingo, E. & Holland, J.J. in The Evolutionary Biology of Viruses Vol. xi (ed. Morse, S.S.) 353 (Raven, New York, 1994).
Domingo, E. Viruses at the Edge of Adaptation. Virology 270, 251–253 (2000).
Loeb, L.A. et al. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. USA 96, 1492–1497 (1999).
Gohara, D.W. et al. Production of “authentic” poliovirus RNA-dependent RNA polymerase (3D(pol)) by ubiquitin-protease-mediated cleavage in Escherichia coli. Prot. Express. Purif. 17, 128–138 (1999).
Racaniello, V.R. & Baltimore, D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 214, 916–919 (1981).
Dea, P., Schweizer, M.P. & Kreishman, G.P. Nuclear magnetic resonance studies of the solution properties of the antiviral nucleoside, 1-beta-D-ribofuranosyl-1,2,4-triazole-3- carboxamide, the coresponding 5′-phosphate, and related triazole nucleosides. Biochemistry 13, 1862–1867 (1974).
Acknowledgements
We thank D. Gohara for preparation of RTP molecular models; S. Scaringe for synthesis of ribavirin phosphoramidite; J. Lecomte for structural analysis of RTP; S. Firestine and J. Herold for discussions; J. Frydman and A. Frankel for comments; and G. Reyes for support. This work was supported in part by a National Cancer Institute National Institutes of Health Howard Temin Award CA75118 (to C.E.C.) and National Institute of Allergy and Infectious Diseases National Institutes of Health grants AI45818 (to C.E.C.) and AI40085 (to R.A.). S.C. is a Howard Hughes Medical Institute doctoral fellow.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Crotty, S., Maag, D., Arnold, J. et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6, 1375–1379 (2000). https://doi.org/10.1038/82191
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/82191
This article is cited by
-
Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects
European Journal of Medical Research (2023)
-
Development of a transcriptome-based determination of innate immune suppressor (TDIS) assay as an in vitro test for immunotoxicity
Archives of Toxicology (2023)
-
A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals
Journal of Translational Medicine (2020)
-
Development of a fluorescence-based method for the rapid determination of Zika virus polymerase activity and the screening of antiviral drugs
Scientific Reports (2019)
-
In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo Hemorrhagic Fever Virus inhibitors
Scientific Reports (2019)